Related by context. All words. (Click for frequent words.) 75 secondary efficacy endpoints 71 secondary efficacy endpoint 70 STRIDE PD 70 noninferiority 69 primary efficacy endpoint 69 secondary endpoint 69 efficacy endpoints 69 Phase Ib study 69 clinical endpoints 68 MEND CABG II 68 composite endpoint 68 primary endpoint 67 prospectively defined 67 apremilast 67 BENICAR HCT 67 CIMZIA ™ 67 phase IIa 67 desvenlafaxine succinate 67 teriflunomide 66 prucalopride 66 morphometric vertebral fractures 66 primary efficacy endpoints 66 ruboxistaurin 66 GAMMAGARD 66 prespecified 66 CIMZIA TM 66 subgroup analyzes 66 elotuzumab 66 nalbuphine ER 66 riociguat 66 refractory AML 66 phase IIb study 65 iniparib 65 rolofylline 65 Phase 2a trial 65 GOUT 65 BAL# [002] 65 secondary endpoints 65 Onrigin 65 prespecified criteria 65 GFT# 65 PRIMO CABG 65 NATRECOR ® 65 ATACAND 65 HuMax EGFr 65 CANCIDAS 65 symptomatic VTE 65 regorafenib 65 MEND CABG 65 dose escalation Phase 64 ACTEMRA TM 64 Ceplene/IL-2 64 Doxil ® 64 cannabinor 64 levosimendan 64 NP2 Enkephalin 64 plasma kallikrein inhibitor 64 dosing cohort 64 MabCampath 64 CTAP# Capsules 64 Xanafide 64 Phase 2b study 64 placebo controlled clinical 64 RSD# oral 64 SVR# 64 phase IIb trial 64 cangrelor 64 Amrubicin 64 phase IIIb 64 analgesic efficacy 64 phase IIb 64 irbesartan 64 midstage clinical trial 64 Traficet EN 64 vidofludimus 64 bicifadine 64 TNF alpha inhibitor 64 RE LY ® 64 elagolix 64 Corlux 64 Dyloject TM 64 Fibrin Pad 64 NLX P# 64 oral ridaforolimus 64 ARB telmisartan 64 virological response 64 MERLIN TIMI 64 NEVO ™ 64 Darusentan 64 primary endpoints 64 oral rivaroxaban 63 ruxolitinib 63 phase Ib 63 Plicera 63 MAGE A3 ASCI 63 salmeterol fluticasone 63 pain palliation 63 Zemplar Capsules 63 varespladib 63 serum phosphate levels 63 chlorambucil 63 rALLy trial 63 MIRCERA 63 Mipomersen 63 Capesaris 63 dosage regimens 63 pharmacokinetic PK 63 Azedra 63 liposomal formulation 63 angiographic outcomes 63 Ocrelizumab 63 FOLPI 63 dexpramipexole 63 ximelagatran 63 TBC# 63 GSK# [001] 63 phase IIa clinical 63 oxymorphone ER 63 vismodegib 63 pharmacokinetic equivalence 63 viral kinetic 63 EDEMA3 63 nab paclitaxel 63 Telintra 63 nonrandomized 63 tecarfarin 63 PASI scores 63 EVIZON 63 dose cohort 63 eplerenone 63 INC# 63 glufosfamide 63 undetectable HBV DNA 63 R# #mg BID 63 clazosentan 63 phase IIb clinical 63 ELACYT 63 ANCHOR trial 63 PRT# 63 achieved statistical significance 63 Elitek 63 preclinically 63 phase 2a 63 pharmacokinetic PK study 63 Proellex TM 63 brivaracetam 63 pharmacodynamic effects 63 mRCC 63 KRN# 63 Phase IIa trial 63 HCV RESPOND 2 63 CR nPR 63 liposomal doxorubicin 63 intravesical therapy 63 Tekamlo 63 Ophena TM 63 EndoTAGTM 1 63 Pemetrexed 63 endoscopic remission 63 randomized blinded 63 trastuzumab emtansine T DM1 63 Fibrillex TM 63 INCB# [003] 63 Phase IIB 62 pharmacokinetic PK profile 62 BENICAR 62 TG# [003] 62 Panzem R NCD 62 plasma pharmacokinetics 62 ribavirin RBV 62 SinuNase 62 #mg BID [001] 62 tolvaptan 62 SPIRIT FIRST 62 SILENOR 62 pharmacodynamic PD 62 MADIT CRT trial 62 SPIRIVA HandiHaler 62 viral kinetics 62 PFO migraine 62 placebo controlled clinical trials 62 MYDICAR 62 eculizumab therapy 62 virologic response 62 Pharmacokinetic parameters 62 Alocrest 62 HuMax CD# 62 Study GL# 62 TAXUS Stent 62 definite stent thrombosis 62 CTEPH 62 Hyphanox 62 MoxDuo TM IR 62 pharmacodynamic properties 62 certolizumab 62 TAXUS VI 62 MoxDuo ® 62 budesonide foam 62 ABSORB trial 62 Androxal TM 62 baminercept 62 ToGA 62 recurrent GBM 62 somatostatin analog 62 ATL# [001] 62 Rezular 62 alvimopan 62 Orazol 62 subanalysis 62 Subgroup analysis 62 Tocosol Paclitaxel 62 EDEMA3 trial 62 gallium nitrate 62 orBec 62 PROMACTA 62 receptor tyrosine kinase inhibitor 62 active comparator 62 Phase IIa trials 62 IV NSCLC 62 anagrelide 62 mITT population 62 Phase Ib clinical 62 surrogate endpoint 62 pharmacokinetics PK 62 atrasentan 62 Phase III randomized controlled 62 antiangiogenic therapy 62 rFVIIa 62 Bezielle 62 zalutumumab 62 corticosteroid dexamethasone 62 double blinded placebo 62 pharmacodynamics PD 62 Pimavanserin 62 Zybrestat 62 docetaxel chemotherapy 62 PROCHYMAL 62 dose limiting toxicities 62 VA# [002] 62 Tarceva TM 62 Bicifadine 62 SinuNase TM 62 Q#IR 62 neratinib 62 dose escalation phase 62 IOP lowering 62 GALNS 62 oral treprostinil 62 beta 1a 62 1mg dose 62 pharmacokinetic characteristics 62 OvaRex MAb 62 lomitapide 62 comparator arm 62 timepoints 62 TNF inhibitor 62 JAK inhibitor 62 elacytarabine 62 Phase 2a clinical 62 Plenaxis TM 61 Allovectin 7 61 death reinfarction 61 aflibercept 61 recurrent glioblastoma multiforme 61 Phase IIb clinical trials 61 cediranib 61 BrachySil TM 61 TRITON TIMI 61 HCV SPRINT 61 PEG IFN 61 PRECiSE 61 midstage study 61 zileuton 61 non inferiority 61 chemoradiotherapy 61 velafermin 61 #mg dose [002] 61 guanfacine extended release 61 Dacogen decitabine 61 TAXUS IV 61 tocilizumab 61 Elocalcitol 61 tanespimycin 61 clevidipine 61 Arikace 61 prospective randomized multicenter 61 complete cytogenetic response 61 lintuzumab 61 BrachySil 61 deferiprone 61 idraparinux 61 liver histology 61 Phase #b/#a trial 61 concurrent chemoradiation 61 aleglitazar 61 trodusquemine 61 multicentre randomized 61 mertansine 61 Candesartan 61 glycated hemoglobin levels 61 oral prodrug 61 AZILECT R 61 sitaxsentan 61 TMC# [002] 61 methylnaltrexone 61 reslizumab 61 Desmoteplase 61 GW# [003] 61 goserelin 61 LymphoStat B belimumab 61 hyperoxaluria 61 huC# DM4 61 Ereska 61 QTc prolongation 61 tipranavir r 61 octreotide implant 61 PROSTVAC TM 61 GLP1 agonist 61 dirucotide 61 paricalcitol 61 AGILECT R 61 Phase #/#a 61 Northera 61 Allovectin 7 ® 61 canakinumab 61 statistical significance 61 Xinlay 61 Nuvion 61 graft dysfunction 61 metastatic CRC 61 Phase 1a clinical 61 relapsed MM 61 haematologic 61 abiraterone acetate 61 Temsirolimus 61 Vernakalant 61 tasocitinib 61 mg/m2 dose 61 tolevamer 61 Aplidin 61 5-fluorouracil/leucovorin 61 Archexin 61 zotarolimus eluting stent 61 clinically meaningful improvement 61 micafungin 61 APEX AMI trial 61 zotarolimus 61 RezularTM 61 calcineurin inhibitor 61 VADT 61 BRIM2 61 evaluable subjects 61 Dacogen injection 61 CAPHOSOL 61 sargramostim 61 VELCADE melphalan 61 Phase IIa clinical 61 tipranavir 61 RoACTEMRA 61 ponatinib 61 Diamyd ® 61 pomalidomide 61 PSMA ADC 61 virologic failure 61 caspofungin 61 KRAS status 61 biologic therapy 61 neurologic progression 61 divalproex sodium 61 DLTs 61 GSK# [002] 61 bovine thrombin 61 briakinumab 61 Dasatinib 61 inhaled iloprost 61 Zerenex 61 Aflibercept 61 MitraClip device 61 gemcitabine cisplatin 61 preclinical efficacy 61 bosutinib 61 APTIVUS r 61 dosage regimen 61 Gabapentin GR 61 VIAject ™ 61 fosbretabulin 61 antidepressant efficacy 61 ularitide 61 TroVax ® 61 CHAMPION PCI 61 timepoint 61 guanfacine 61 pimecrolimus 61 maximally tolerated dose 61 MoxDuo IR 61 Lu AA# 61 fluoropyrimidine 61 Chemophase 61 figitumumab 61 urinary N telopeptide 61 Zenvia ™ 61 GP IIb IIIa inhibitor 61 Cimzia TM 61 cinacalcet 61 trial evaluating PRX# 61 Dextofisopam 61 mesalamine granules 61 ORMD 61 novel oral anticoagulant 61 Primary endpoints 61 postoperative chemotherapy 61 HuMax CD4 60 randomized multicenter trial 60 RRMS patients 60 registrational trial 60 opioid induced bowel dysfunction 60 non metastatic osteosarcoma 60 dose titration 60 CCX# 60 dose cohorts 60 cetrorelix pamoate 60 placebo controlled Phase 60 GRN# 60 rALLy 60 tranylcypromine 60 gemcitabine carboplatin 60 low dose cytarabine 60 incyclinide 60 Degarelix 60 ischemic cardiomyopathy 60 ACR# responses 60 ADVANCE PD 60 clinically meaningful improvements 60 Torisel 60 mycophenolate mofetil MMF 60 hematologic toxicity 60 HBeAg positive patients 60 eprotirome 60 Cloretazine 60 mitoxantrone plus 60 randomized Phase IIb 60 Aryplase 60 acute HAE attacks 60 trastuzumab DM1 60 CLARITY study 60 MoxDuo ® IR 60 ADAGIO study 60 BEMA TM Fentanyl 60 MGd 60 clinically meaningful efficacy 60 rindopepimut 60 huN# DM1 60 severe gastroparesis 60 T Pred 60 intravesical 60 EGS# 60 mcg albinterferon alfa 2b 60 BoNTA 60 galiximab 60 APTIVUS R 60 teduglutide 60 carotid endarterectomy CEA 60 Troxatyl 60 melphalan prednisone 60 enzastaurin 60 cariprazine 60 MAP# 60 Octreolin 60 RAPAFLO 60 multicenter Phase II 60 PEGINTRON TM 60 TACI Ig 60 remission CR 60 CHAMPION PLATFORM 60 ALB # 60 ZOLINZA 60 VEGF inhibitor 60 Phase IIb clinical 60 Pegylated Liposomal Doxorubicin 60 favorable pharmacokinetic profile 60 trastuzumab Herceptin ® 60 ancrod 60 NasalFent 60 UPLYSO 60 diabetic neuropathic pain 60 CR CRu 60 AeroLEF 60 motesanib 60 ROCKET AF 60 Glypromate 60 solifenacin 60 PDE4 inhibitor 60 MVA MUC1 IL2 60 alagebrium 60 DAPT 60 eosinophilic asthma 60 FOSRENOL ® 60 PEG PAL 60 TKM ApoB 60 Vicinium TM 60 HuLuc# 60 REMINYL ® 60 tolerated dose MTD 60 OMNARIS HFA 60 O PPDS 60 Teriflunomide 60 LB# [003] 60 pharmacokinetic parameters 60 pertuzumab 60 LHRH antagonists 60 IPL# 60 subcutaneously administered 60 EOquin 60 insulin degludec 60 Phase IIIb clinical 60 adalimumab 60 binary restenosis 60 CoFactor 60 everolimus eluting stents 60 Aurexis 60 TLK# 60 ACR# response 60 randomized Phase 2b 60 prospective multicenter randomized 60 PEGylated interferon beta 1a 60 Nexavar sorafenib 60 edoxaban 60 solithromycin 60 Synavive 60 ibandronate 60 BRIM3 60 Acute Ischemic Stroke 60 methotrexate therapy 60 peg interferon 60 DCCR 60 #mg QD [002] 60 muraglitazar 60 Fodosine 60 generation purine nucleoside 60 APTIVUS 60 RE LY 60 azilsartan medoxomil 60 decitabine 60 PNH patients 60 multicenter placebo controlled 60 CA9 SCAN 60 platelet inhibition 60 sunitinib malate 60 TWYNSTA 60 TH# [003] 60 metabolic parameters 60 AZD# 60 macroalbuminuria 60 Dapagliflozin 60 rilonacept 60 Diamyd R 60 metastatic malignant melanoma 60 ACZ# 60 dopamine partial agonist 60 ocular formulation 60 statistical significance p 60 ospemifene 60 XIENCE V PROMUS Stent 60 pharmacodynamic endpoints 60 metformin monotherapy 60 GRAVITAS trial 60 Firazyr 60 USL# 60 relapsed refractory multiple myeloma 60 mGluR5 NAM 60 HBeAg seroconversion 60 ELND# 60 YONDELIS 60 ACR# ACR# 60 UA NSTEMI 60 lumiliximab 60 antithrombotic therapy 60 oral FTY# 60 FOLFOX6 60 Telcyta 60 ALGRX 60 RLY# 60 limiting toxicity 60 Valdoxan 60 Onconase 60 BAY #-# 60 icatibant 60 multicenter randomized placebo controlled 60 davunetide intranasal AL 60 TRO# 60 coronary stenosis 60 pharmacodynamic 60 combretastatin A4 phosphate CA4P 60 LIALDA 60 PegIntron 60 nicardipine 60 neurogenic orthostatic hypotension 60 achieved ACR# 60 ocrelizumab 60 ozarelix 60 ara C 60 SIMPADICO 60 DDP# 60 EXPAREL ™ 60 NATRECOR R 60 pediatric acute lymphoblastic 60 cytogenetic response 60 AEGR 60 Zevalin consolidation 60 Pharmacokinetic studies 60 milrinone 60 CLORETAZINE TM VNP#M 60 locoregional recurrence 60 HbA 1c 60 lenalidomide dexamethasone 60 eculizumab 60 EndoTAG TM -1 60 Neurodex 60 terlipressin 60 adenoma recurrence 60 Pegasys plus Copegus 60 colorectal liver metastases 60 RSR# 60 Prestara 60 Sym# 60 CRLX# 60 oral Xeloda 60 Phase IIb trials 60 alicaforsen enema 60 Oral NKTR 60 tapentadol ER 60 Phase #b/#a clinical 60 CorVue ™ 60 cardiovascular morbidity 60 INCB# [001] 60 Vidaza azacitidine 60 platinum refractory 60 oxycodone CR 60 ProSavin 60 AZILECT ® 60 macrolide antibiotic 60 Solid Tumors criteria 60 Ranibizumab 60 unblinded 60 EDARBI 60 Phase 2a 60 6R BH4 60 XIENCE TM 59 Vectibix monotherapy 59 ZACTIMA 59 AMEVIVE 59 oral diclofenac 59 oral anticoagulant therapy 59 enoximone 59 OHR/AVR# 59 hemoglobin A1c levels 59 EOquin TM 59 statistically significant efficacy 59 Phase 1b 59 Phase Ib II 59 gemtuzumab ozogamicin 59 Clolar ® 59 HORIZONS AMI trial 59 naltrexone SR 59 SLx 59 bepotastine besilate nasal spray 59 afamelanotide 59 VIAject 59 NV1FGF 59 efficacy tolerability 59 HyQ 59 non squamous NSCLC 59 IRESSA 59 antiviral efficacy 59 cytotoxic therapy 59 CALGB # [001] 59 AST ALT 59 metastatic hormone refractory 59 sipuleucel T 59 β blockers 59 Relivar 59 confirmatory clinical 59 volociximab 59 Phase IIa 59 MyVax 59 PSN# [002] 59 Kaplan Meier analysis 59 latanoprost 59 genotypic resistance 59 mCRC patients 59 Targretin capsules 59 JAK inhibitors 59 CytoFabTM 59 mg kg dose 59 CRp 59 Neuradiab 59 pamidronate 59 sunitinib 59 assessing T DM1 59 postintervention 59 basal bolus regimen 59 gepirone ER 59 LCP Tacro 59 IMA# 59 Phenoptin 59 Relovair 59 trabectedin 59 QNEXA 59 AVADO 59 MGN# 59 CIMZIA TM certolizumab pegol 59 sorafenib Nexavar 59 EFAPROXYN 59 VAPRISOL 59 DepoDur TM 59 MCyR 59 pegylated liposomal doxorubicin 59 AQ4N 59 Exelixis compounds 59 romiplostim 59 pioglitazone HCl 59 pregabalin 59 IIa trial 59 HER2 positive metastatic breast 59 Safinamide 59 prospective randomized controlled 59 Natalizumab 59 TEMODAL 59 QuadraSphere 59 CRMD# 59 Degludec 59 midstage clinical 59 prospective multicenter study 59 heavily pretreated patients 59 anticancer compound 59 aclidinium 59 SYNTAX trial 59 lanthanum carbonate 59 IRX 2 59 olaparib 59 doxorubicin docetaxel 59 #mg/m# [002] 59 paclitaxel Taxol R 59 MoxDuo 59 PS# [001] 59 chronic thromboembolic pulmonary 59 confirmatory Phase III 59 omacetaxine mepesuccinate 59 fluvastatin 59 indibulin 59 pharmacokinetic pharmacodynamic 59 samalizumab 59 arbaclofen 59 bortezomib Velcade 59 zonisamide SR 59 myocardial revascularization 59 OMAPRO 59 Dose escalation 59 dexanabinol 59 ACCORD Lipid 59 EDEMA4 59 preoperative chemotherapy 59 PSN# [001] 59 bolus dose 59 adjuvant colon cancer 59 CR# vcMMAE 59 Benlysta belimumab 59 sustained virologic response 59 EmbraceAC 59 pivotal bioequivalence 59 CCyR 59 remission induction 59 Trabectedin 59 AXIRON ™ 59 BARI 2D 59 ARCOXIA 59 gefitinib Iressa 59 bolus injection 59 SYMMETRY trial 59 liposomal amphotericin B 59 HbA 1c levels 59 PD LID 59 mg/m2 cohort 59 Betaferon R 59 Prostate AdenoCarcinoma Treatment 59 bosentan 59 XmAb# 59 delafloxacin 59 systemically administered 59 urocortin 2 59 Solesta 59 TriRima 59 eltrombopag 59 visilizumab 59 histamine dihydrochloride 59 MVax 59 intermittent dosing 59 obatoclax 59 Non inferiority 59 NO# [002] 59 doxorubicin cyclophosphamide 59 FOLFIRI 59 intravenous dosing 59 antihypertensive therapy 59 aldosterone antagonist 59 Itopride 59 chemoradiation therapy 59 ACUROX ® 59 antiarrhythmic drugs 59 fulvestrant 59 cortical stimulation 59 dipyridamole plus 59 Phase 2b trial 59 liprotamase 59 CA4P 59 Aptivus ® 59 DermaVir Patch 59 cytoreduction 59 placebo controlled studies 59 FOLFOX4 59 oblimersen 59 Navelbine ® 59 PSA nadir 59 posaconazole 59 SABCS 59 temsirolimus 59 INTEGRILIN 59 antiarrhythmic drug 59 liver transplant recipients 59 SCr 59 inhibitor RG# 59 rosuvastatin #mg 59 #mg BID [003] 59 intravenous diuretics 59 imatinib therapy 59 relapsed SCLC 59 IVTA 59 Pirfenidone 59 iSONEP 59 dorzolamide 59 LCP Tacro TM 59 GLP toxicology studies 59 RhuDex ® 59 TMC# r 59 mcg BID 59 alvespimycin 59 APEX PD 59 Zarnestra 59 postprocedure 59 Prosaptide 59 invasive aspergillosis 59 satraplatin Phase 59 mecamylamine 59 Solorel TM 59 evaluating REVLIMID 59 Phase Ib 59 serum phosphorous 59 paclitaxel eluting stents 59 LymphoStat B TM 59 CLIRS 59 TEMSO 59 MIRAPEX ER 59 periprocedural 59 administered subcutaneously 59 vandetanib 59 iclaprim 59 dose dose escalation 59 Tasimelteon 59 favorable tolerability 59 Virulizin ® 59 exploratory endpoints 59 Zenvia TM 59 bardoxolone 59 QVA# 59 Reverset 59 LEXIVA r 59 almorexant 59 Carfilzomib 59 Secondary efficacy endpoints 59 Ketotransdel 59 vaso occlusive crisis 59 Anturol TM 59 infusional 5-FU/LV 59 Tyrima 59 Xelox 59 VITAL Trial 59 plus COPEGUS 59 pseudobulbar affect PBA 59 Phase #/#a trial 59 Aggrastat ® tirofiban hydrochloride 59 gadobutrol 59 antipsychotic efficacy 59 bupropion SR 59 leukemia AML 59 TRIOLEX 59 Phase 1b clinical trials 59 midstage clinical trials 59 vildagliptin 59 drug eluting stent DES 59 estramustine 59 malignant ascites 59 Aclidinium 59 IGF 1R inhibitor 59 INVEGA ® 59 serum urate 59 ILUVIEN ® 59 cilostazol 59 DOXIL 59 Apoptone 59 M6G 59 orally inhaled migraine 59 mitomycin 59 noninferior 59 Phase 1b trial 58 carboplatin paclitaxel 58 trials RCTs 58 Phase III ADT 58 TAXUS Liberte Stent 58 docetaxel Taxotere 58 COMFORT II 58 Multiple Ascending Dose 58 pegylated interferon alfa 2b 58 KNS # 58 Zoraxel 58 PREZISTA r arm 58 Femara letrozole 58 bevacizumab Avastin 58 RhuDex TM 58 AVERROES 58 Votrient 58 FOLFIRINOX 58 AzaSite Plus 58 rt PA 58 AeroLEF TM 58 mTOR inhibitor 58 Phase 2b kidney transplant 58 treprostinil 58 prespecified secondary 58 PARTNER Trial 58 mg BID dose 58 DEB# 58 EGFR TKI 58 FOLFOX regimen 58 serum uric acid sUA 58 ABC/3TC 58 CYPHER Stent 58 coronary intervention 58 immunomodulatory therapy 58 Golimumab 58 superficial bladder cancer 58 tolerability profiles 58 metaglidasen 58 GLYX 58 androgen suppression 58 dosing cohorts 58 mycophenolate mofetil 58 arzoxifene 58 alemtuzumab treated 58 clobazam 58 Viprinex TM 58 titration phase 58 QT QTc 58 EchoCRT 58 A1c levels 58 ENDEAVOR II 58 undetectable HCV RNA 58 rEV# 58 peginterferon 58 TLUS 58 bendamustine 58 PIX# [002] 58 Dual Opioid 58 specified secondary endpoints 58 TOLAMBA 58 median PFS 58 unresectable HCC 58 NAbs 58 GnRH agonist 58 intravenous cyclophosphamide 58 #mg dose [003] 58 sirolimus eluting stent 58 Secondary endpoints 58 locoregional 58 progression TTP 58 Quinamed 58 rufinamide 58 detectable HCV RNA 58 Flu Cy 58 Canvaxin TM 58 cisplatin vinorelbine 58 NSABP C 58 TASKi3 58 T2DM 58 anti angiogenic therapy 58 Cimzia ® certolizumab pegol 58 postoperative mortality 58 KRAS mutations occur 58 custirsen 58 PREZISTA r